| Jun 3 |
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
|
| May 29 |
Neurocrine Biosciences to Participate at Investor Conferences in June
|
| May 28 |
Neurocrine Biosciences CEO Gorman stepping down in October
|
| May 28 |
Neurocrine Biosciences Announces CEO Succession Plan
|
| May 28 |
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
|
